Flunixin meglumine is approved in cattle for which of the following conditions?

• A. Insulin resistance
• B. Fever from respiratory disease
• C. Chronic kidney disease
• D. Gastrointestinal ulcers

Answer: (B)

Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID) that is widely used in veterinary medicine, particularly for its analgesic and anti-inflammatory properties. In cattle, one of the primary approved indications for flunixin meglumine is the treatment of fever associated with respiratory diseases. This is significant because respiratory diseases in cattle can lead to substantial morbidity and, if not addressed, increased mortality.

The ability of flunixin to reduce fever can help improve the animal's overall well-being, enhance feed intake, and support recovery. Its action on the cyclooxygenase (COX) enzymes helps to decrease the production of prostaglandins, which are involved in inflammation and fever. Therefore, when cattle exhibit fever related to respiratory infections, flunixin meglumine provides a valuable therapeutic intervention.

The other conditions listed do not have an approved indication for flunixin meglumine in cattle. While NSAIDs may have roles in managing other health issues, such as pain in gastrointestinal disorders, chronic kidney disease, or insulin resistance, flunixin specifically does not carry approvals for those conditions in cattle. This understanding clarifies why the approved use of flunixin meglumine is particularly relevant to managing fever from respiratory diseases, making it